Staar Surgical Company has announced its proposed merger with Alcon, which has led to a significant change in the company's financial metrics. In the press release, Staar Surgical Company reported that revenues for the third quarter of 2025 increased to $55.6 million, up from $43.6 million in the same period last year. Moreover, the company's gross margin for the third quarter of 2025 improved to 68.4%, compared to 66.2% in the third quarter of 2024. Additionally, the press release noted that the company's net income attributable to common stockholders increased to $9.5 million in the third quarter of 2025, up from $6.1 million in the third quarter of 2024.
Furthermore, the press release highlighted that the company's non-GAAP net income for the third quarter of 2025 was $11.8 million, marking a significant increase from $7.3 million in the same period last year. Additionally, the company's non-GAAP earnings per share for the third quarter of 2025 were $0.25, up from $0.16 in the third quarter of 2024. These figures demonstrate the positive impact of the merger with Alcon on Staar Surgical Company's financial performance.
Moreover, the company's cash and cash equivalents as of September 26, 2025, totaled $103.3 million, compared to $86.4 million as of December 27, 2024. This increase in cash and cash equivalents signifies a strengthened financial position for Staar Surgical Company following the proposed merger with Alcon.
Following these announcements, the company's shares moved 0.11%, and are now trading at a price of $26.78. Check out the company's full 8-K submission here.
